PROSTATE CANCER

This early-stage study tests a personalized vaccine (PGV001) combined with an immune booster (CDX-301) in 27 men who have had aggressive prostate cancer but currently show no signs of tumor. The goal is to see if the vaccine is safe and can train the immune system to recognize an…

This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to seek out and destroy cancer cells that have a specific marker called PSMA. The trial will check…

This trial tests whether giving a lower dose of radiation in just two sessions can reduce urinary side effects for men with intermediate-risk prostate cancer. All participants receive radiation on an MR-Linac, a machine that combines MRI imaging with radiotherapy for precise targ…

This study compares two types of radiation therapy for men with favorable or low-tier intermediate risk prostate cancer: low dose rate (LDR) brachytherapy, which uses permanent radioactive seeds, and high dose rate (HDR) brachytherapy, which uses temporary radioactive material. T…

This study looks at whether adding a precise type of radiation (SBRT) to intermittent hormone therapy can better control prostate cancer that has spread to a few places in the body. The trial involves 60 men whose cancer was detected by a special PET scan but not by standard scan…

This study follows over 800 men with non-metastatic castration-resistant prostate cancer who are already taking darolutamide as part of their normal care. Researchers are tracking side effects and how well the drug controls the cancer in real-world conditions, outside of a strict…

This study tests whether adding the immune-boosting drug Sipuleucel-T (Provenge) to standard hormone therapy can help men with advanced prostate cancer that is no longer responding to hormones alone. The trial involves 26 participants who will receive either Sipuleucel-T alone or…

This trial tests a minimally invasive treatment that uses microwaves to destroy only the cancerous part of the prostate, leaving healthy tissue intact. The goal is to control the cancer while avoiding common side effects of full prostate removal, such as urine leakage and erectil…

This study tests a new long-acting injection called Debio 4228 for men with advanced prostate cancer. The goal is to lower testosterone levels to control the cancer. About 55 men will receive different doses to find the best one. This is not a cure, but a way to manage the diseas…

This early-stage study tests whether combining a radioactive drug (177Lu-PSMA-617) with precise radiation therapy (SBRT) is safe for men with hormone-sensitive prostate cancer that has spread to a few other spots in the body. The drug seeks out and attacks cancer cells, while the…

This phase 2 trial tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can improve outcomes for men with castration-resistant metastatic prostate cancer. About 60 participants will receive either one or two DNA vaccines along with pembrolizumab f…

This study is for men whose prostate cancer has returned in the same area after they already had radiation and surgery. The researchers want to see if giving a very precise, high-dose radiation treatment (called SBRT) along with the diabetes drug metformin can safely control the …

This study tests whether a device called Calypso, which tracks the prostate's position in real time during radiation, can reduce long-term side effects compared to standard image-guided radiation. 74 men with low- or intermediate-risk prostate cancer took part. The goal is to see…

This study tests a biodegradable balloon, called a rectal spacer, placed between the prostate and rectum before radiation therapy for prostate cancer. The goal is to see if it safely reduces radiation exposure to the rectum, potentially lowering side effects. Up to 150 men with l…

This study is testing whether giving high-dose radiation only to the tumor area (focal HDR brachytherapy) can control early-stage prostate cancer while causing fewer side effects than treating the whole gland. Sixty men with low- or favorable intermediate-risk prostate cancer wil…

This study looks at how prostate cancer treatments, especially hormone therapy, affect heart health. It includes two parts: one that follows men over time to track heart problems, and another that tests whether a program of healthy eating, exercise, smoking cessation, and medicat…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This study looks at whether a whole-food, plant-based diet can help overweight or obese men with prostate cancer who are on hormone therapy (ADT) control their weight and reduce inflammation. About 76 men will either receive free plant-based meals at home or standard nutrition ad…

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with intermediate-risk, localized prostate cancer. The goal is to control the cancer while avoiding common side effects like incontinence and impotence. About 400 men …

This phase 2 trial is testing whether adding the drug sunitinib to standard hormone therapy can shrink or control high-risk prostate cancer before the prostate is removed. About 64 men with localized but aggressive prostate cancer will receive sunitinib pills plus a hormone block…

This study tests a gel called SpaceIT that is placed between the prostate and rectum before radiation therapy for prostate cancer. The gel acts as a spacer to reduce radiation reaching the rectum, potentially lowering side effects. About 230 adults with low- to intermediate-risk …

This phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This phase 2 trial tests whether a personalized walking program can slow the progression of localized prostate cancer in men who are on active surveillance (monitoring instead of immediate treatment). The 36 participants will exercise up to 5 times per week for 225-300 minutes to…

This phase 3 trial tests whether adding apalutamide (a daily pill) to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer live longer and delay disease progression. Over 1,000 participants received either apalutamide plus hormone therapy or a plac…

This phase 2 trial is testing a drug called sacituzumab govitecan in 31 men with metastatic castration-resistant prostate cancer that has worsened despite hormone therapy. The drug works like a smart bomb, delivering chemotherapy directly to cancer cells. Researchers are measurin…

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This phase 2 trial tests a DNA vaccine (pTVG-HP) plus the immunotherapy drug nivolumab in 19 men whose prostate cancer has returned after surgery but has not spread. The goal is to see if the combination can safely lower PSA levels to undetectable and delay cancer spread. Partici…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This study tests a newer, highly precise radiation technique for men with high-risk prostate cancer. The treatment delivers a strong dose to the pelvic lymph nodes while boosting radiation to the prostate itself. Researchers want to see if this approach controls the cancer better…

This study tests whether a Mediterranean diet is practical for medically underserved men with prostate cancer. Over 8 weeks, 25 participants receive fresh fruits, vegetables, olive oil, and walnuts, plus personalized education. The goal is to see if this diet is safe and feasible…

This Phase 3 trial compares two hormone therapies (GnRH antagonist vs GnRH agonist) given alongside radiation for men with very high-risk localized or locally advanced prostate cancer. The main goal is to see which combination better delays cancer progression. The study enrolled …

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study aimed to see if giving the immunotherapy drug pembrolizumab before radical prostatectomy could reduce lymph node invasion in high-risk prostate cancer patients. Participants would have received three doses of the drug before surgery. However, the study was withdrawn be…

This phase 3 trial compares the standard chemotherapy docetaxel alone versus docetaxel plus radium-223 in 732 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if adding radium-223 helps patients…

This early-phase trial tests whether giving higher doses of radiation to the prostate in fewer sessions (while also treating pelvic lymph nodes) is safe for men with intermediate- to high-risk prostate cancer. The study enrolls 18 adults and uses proton beam therapy delivered fou…

This phase 3 trial tested enzalutamide (Xtandi) plus leuprolide in over 1,000 men with high-risk prostate cancer that had not spread but was progressing after initial treatment. The goal was to see if the combination could delay the cancer from spreading to other parts of the bod…

This phase 2 study tests nivolumab (Opdivo) in 29 men with high-risk prostate cancer that has returned after initial treatment, shown by rising PSA levels. The drug works by helping the immune system recognize and attack cancer cells. The main goal is to see if nivolumab can cont…

This phase 3 trial tests whether adding radiation to the whole pelvis, along with standard hormone therapy and prostate radiation, helps men with intermediate- or high-risk prostate cancer live longer. About 2,590 men are taking part. The study compares standard treatment (hormon…

This study tests whether adding the drug darolutamide before and after surgery helps men with high-risk or locally advanced prostate cancer. About 240 men will either have surgery alone or surgery plus the drug. The goal is to see if the drug delays the cancer from coming back or…

This study tests whether a 16-week home-based high-intensity interval training (HIIT) program can slow prostate cancer in Black men who are on active surveillance (monitoring the cancer without immediate treatment). The trial involves 68 participants who will use a stationary bik…

This study looks at men whose prostate cancer has come back in a few spots (oligometastatic) and who have certain gene mutations. It compares standard care (hormone therapy plus radiation) against the same treatment plus a 6-month course of two drugs (niraparib and abiraterone wi…

This study tests whether adding darolutamide to standard hormone therapy and radiation can delay cancer spread in men with very high-risk localized prostate cancer. About 1,100 men are participating in this phase 3 trial. The goal is to see if the combination helps keep the cance…

This phase II trial tests whether using MRI to map the exact location of recurrent prostate cancer after prostatectomy allows doctors to safely deliver a higher radiation dose to the tumor while sparing healthy tissue. The study enrolled 37 men whose PSA levels rose after surgery…

This study tests a combination of a targeted drug (niraparib), hormone therapy, and precise radiation for men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach improves the chance of staying cancer-free for three years. …

This small study tests whether a 3D ultrasound system can help doctors place extra radioactive iodine seeds precisely into prostate tumors. Fifteen men with low- or intermediate-risk prostate cancer will receive the boost during standard brachytherapy. The main goal is to see if …

This study tests a low dose of a radioactive drug called 225Ac-LNC1011 in 16 men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly. The goal is to see if it safely shrin…

This study tests a combination of two radiation techniques—brachytherapy and SBRT—guided by MRI for men with unfavorable prostate cancer. The goal is to achieve high cancer control rates while keeping serious side effects low. About 40 participants will be enrolled to see if this…

This phase 2 trial tests a combination of hormone therapy, external beam radiation, and MRI-guided internal radiation implants for men with unfavorable-intermediate to very high-risk prostate cancer. The goal is to see if this precise approach causes fewer urinary side effects th…

This study tests whether giving a mix of hormone-lowering medications (apalutamide, abiraterone, prednisone, and a GnRH drug) for a few months before surgery can shrink very high-risk prostate cancer and reduce the chance of it coming back. About 102 men with localized or low-vol…

This study tests a precise radiation technique called adaptive SBRT for men with high-risk or unfavorable intermediate-risk prostate cancer. The treatment targets the prostate and pelvic lymph nodes while giving an extra radiation boost to tumor spots seen on MRI. The goal is to …

This study tests whether adding the drug abemaciclib to standard treatment (abiraterone acetate plus prednisone) can help men with metastatic castration-resistant prostate cancer live longer without their cancer getting worse. About 393 participants will receive either the combin…

This trial was designed to test whether robotic telesurgery—where a surgeon operates a robot from a different location—could safely treat prostate cancer using high-intensity focused ultrasound (HIFU). The study was withdrawn before enrolling any participants, so no data on safet…

This pilot study is testing a device that uses ultrasound images to guide a laser or freezing probe directly into prostate tumors. The goal is to destroy only the cancerous tissue while sparing healthy areas. Thirty men with low- to intermediate-risk prostate cancer that hasn't s…

This early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…

This study tests whether giving a higher dose of radiation (up to 81 Gy) to men with high-risk prostate cancer can better control the disease without causing too many side effects. About 251 men who also need hormone therapy will receive targeted radiation using a precise techniq…

This study looks at whether a special gene test can help men with low-risk prostate cancer decide to monitor their cancer instead of treating it right away. About 805 men with early-stage prostate cancer will be randomly assigned to have the gene test or not. The goal is to see i…

This study tests a precise form of proton radiation for men with low- or intermediate-risk prostate cancer. The goal is to see if this approach causes fewer severe side effects than standard X-ray-based radiation. About 61 men will receive 5 treatments over 10 days and be monitor…

This study compares two ways of doing robotic prostate surgery in men with intermediate- to high-risk prostate cancer. One method enters from the back of the prostate, the other from the front. The goal is to see which approach better preserves urinary control and erectile functi…

This early-stage trial tests whether combining a targeted radiation drug (177Lu-PSMA-617) with chemotherapy (carboplatin) is safe and can shrink tumors in men with metastatic castration-resistant prostate cancer. About 37 men will receive the combination to find the best dose and…

This study follows nearly 1,000 prostate cancer patients taking ORGOVYX (relugolix) to see how the drug works in everyday medical practice. Researchers will track side effects, quality of life, and disease progression. The goal is to understand the drug's real-world safety and ef…

This phase 2 trial tests whether a radioactive antibody called 177Lu-J591, combined with the hormone-blocking drug ketoconazole, can prevent prostate cancer from spreading in high-risk patients. The study enrolls 55 men whose PSA is rising despite hormone therapy but who have no …

This Phase 3 trial tests whether adding talazoparib (a targeted drug) to standard hormone therapy (enzalutamide) works better than hormone therapy alone for men with metastatic prostate cancer that has a specific DNA repair mutation. About 600 men are participating. The study mea…

This pilot study tests two ultra-high-dose radiation schedules in 31 men with intermediate-risk prostate cancer. One group gets five high-dose sessions over a week; the other gets a single massive dose. The goal is to see if these shorter treatments are safe and can control the c…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study tests whether a daily dose of green tea catechins (a natural compound) can prevent low- to intermediate-risk prostate cancer from getting worse in men who are not receiving immediate treatment. Over 24 months, 115 men will receive either the green tea extract or a plac…

This study tests whether adding the immunotherapy drug nivolumab (Opdivo) to standard radiation and hormone therapy is safe and effective for men with a very aggressive form of prostate cancer (Gleason grade group 5). About 44 men will receive the drug combination. The goal is to…

This phase 2 trial tests whether a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells, can slow cancer growth better than standard chemotherapy (docetaxel) in 200 men with advanced prostate cancer that has stopped responding to hormone therapy.…

This study tests a new approach for men with intermediate-risk prostate cancer. First, doctors use electric pulses (IRE) to destroy tumor cells, followed by precise radiation (MRgRT). The goal is to see if this combination is safe and can keep cancer away for at least a year. Abo…

This study tests whether a combination of two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the dru…

This study compares two drugs, mannitol and nitroglycerin, given during robotic prostate or bladder surgery to prevent acute kidney injury. The surgery can reduce blood flow to the kidneys, and these drugs may help protect them. 90 adults with normal or mildly reduced kidney func…

This study tests whether giving a precise, high-dose radiation treatment (SBRT) before prostate removal surgery is safe and effective for men with high-risk prostate cancer. Sixteen men with aggressive prostate cancer (Gleason score 8 or higher or signs of spread) will receive ra…

This study tests whether using a lung ultrasound during robotic prostate or bladder surgery can help doctors set the breathing machine to the right pressure, reducing lung collapse and other breathing problems. 88 adults with mild or no lung disease are enrolled. The approach is …

This study tests whether a one-time procedure called brachytherapy, where tiny radioactive seeds are placed directly into the prostate, can control intermediate risk prostate cancer without needing additional treatments. Three hundred men with specific tumor features (Gleason sco…

This study tests whether a very short course of MRI-guided radiation (just 5 sessions) is safe and effective for men with low- or intermediate-risk prostate cancer. Traditional radiation can take 7-8 weeks, but this approach aims to cut that time dramatically. The trial involves …

This study tests whether using advanced MRI scans to guide radiation therapy can reduce side effects for men with localized prostate cancer. Depending on their MRI results, patients receive either a short course of radiation or a longer treatment with a targeted boost to visible …

This study looks at whether testosterone levels can return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and …

This study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if it can shrink tumors or lower PSA levels, and to check for side effects. Researchers also look for markers to predict who might ben…

This study follows 3000 men with prostate cancer to compare how proton therapy and standard photon radiation affect quality of life and side effects like bowel urgency. Participants receive standard care at proton or photon centers, and researchers track bowel, urinary, and sexua…

This study tests a radioactive drug (177Lu rhPSMA-10.1) alone or with hormone therapy in men with high-risk prostate cancer before they have surgery. The goal is to see if the drug is safe and can shrink the tumor. Only 6 men are taking part in this early-phase trial.

This study tests whether using MRI guidance to deliver an extra dose of radiation directly to the tumor can improve prostate cancer treatment. Forty men with localized prostate cancer will receive standard radiation to the whole prostate plus a targeted boost to the visible tumor…

This phase 2 study tests a combination of radiation, hormone therapy (ADT), and two drugs (abiraterone and olaparib) in 21 men with prostate cancer that has spread to a few spots in the body. The goal is to see if this approach can prevent the cancer from growing or spreading fur…

This study tests an experimental oral drug, MRT-2359, in adults with certain advanced cancers, including lung cancer, lymphoma, and other solid tumors driven by MYC genes. The first part finds the safest dose; the second part checks if the drug shrinks tumors. About 174 participa…

This study tests whether giving radiation in just 5 treatments over 2 weeks is as safe and effective as the standard 20 treatments over 4 weeks for men whose prostate cancer has come back after surgery. The 134 participants will be randomly assigned to one of the two schedules. T…

This phase 1 trial is testing a precise, high-dose radiation technique called SABR for men with high-risk prostate cancer. The goal is to find the highest safe dose to the prostate and pelvic lymph nodes while monitoring side effects. Sixty participants will receive five radiatio…

This study tests whether giving an extra-high dose of radiation to the most aggressive parts of prostate tumors, guided by MRI, can better control cancer while reducing side effects. About 164 men with prostate cancer will receive either the standard radiation or the standard plu…

This early-phase study tests a new type of immunotherapy for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are genetically modified to better recognize and attack prostate cancer cells while …

This study tests a new way to deliver high-dose radiation (SABR) for low- and intermediate-risk prostate cancer. The technique, called SUPR-SABR, is designed to avoid the urethra, rectum, and pudendal artery to reduce urinary and bowel side effects. About 42 men will receive five…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests a radioactive drug called 225Ac-J591 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The first part finds a safe dose and schedule, and the second part checks if the drug lowers PSA levels by more than half. About 6…

This study tests whether giving a combination of two hormone therapies (leuprorelin and darolutamide) for 24 weeks before prostate removal surgery can reduce or eliminate cancer more effectively than either drug alone. It involves 144 men with intermediate to high-risk prostate c…

This phase 2 trial is testing a combination of two hormone-based drugs—darolutamide and high-dose testosterone—in 51 men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The approach, called extreme bipolar androgen…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This Phase 2 trial tests whether drinking three cups of ArtemiCoffee (made from the Artemisia annua plant) daily for 24 weeks can lower PSA levels in 20 men whose prostate cancer has returned after initial treatment. The goal is to see if at least half of the men experience a 50%…

This phase II study tests whether giving an extra-high radiation dose directly to the main prostate tumor, while treating the rest of the prostate with standard SBRT, can reduce the chance of cancer coming back. About 91 men with intermediate-risk prostate cancer will receive fiv…

This study compares two radiation methods for men with low- or intermediate-risk prostate cancer: low dose rate (permanent seed implants) and high dose rate (temporary radioactive needles). The main goal is to see which approach better preserves urinary quality of life. About 140…

This study compares three different radiotherapy techniques for prostate cancer: standard treatment, a shorter course (SBRT), and a booster approach. Over 500 participants are being followed to see which method best controls cancer while minimizing side effects and preserving qua…

This trial compares two types of brachytherapy boost (HDR vs LDR) given alongside external beam radiation for intermediate- and high-risk prostate cancer. The goal is to see which one provides better cancer control and quality of life with fewer side effects. About 195 men are ta…

This study is testing a new drug called xaluritamig in men whose prostate cancer has returned after initial treatment but has not spread. The main goal is to see if the drug is safe and tolerable. About 50 participants will receive the drug, and researchers will monitor side effe…

This phase 2 trial tests whether adding enzalutamide to standard hormone therapy and chemotherapy can better control metastatic prostate cancer that still responds to hormones. About 40 men with advanced disease will receive all three drugs. The main goal is to see how many achie…

This program offers expanded access to NanoPac, a cancer treatment, for people with advanced pancreatic, prostate, or lung cancer who cannot join ongoing clinical trials. The goal is to provide the drug to those who have no other options. However, the program is no longer availab…

This study compares a standardized active surveillance protocol to usual care for men with low-risk prostate cancer. The goal is to see if a clear set of rules for when to start treatment can reduce unnecessary treatments and side effects without raising the risk of cancer spread…

This early-stage trial tests whether a patient's own immune cells can be genetically modified to recognize and attack prostate cancer cells. Thirteen men with advanced prostate cancer that no longer responds to hormone therapy will receive infusions of their own engineered T cell…

This study looks at whether removing the prostate and nearby lymph nodes, in addition to standard drug therapy, helps men with prostate cancer that has spread to a few bones live longer and delay the cancer becoming resistant to treatment. About 452 men with intermediate- or high…

This study is for men whose prostate cancer has returned after surgery, shown by a rising PSA. It compares standard hormone therapy plus radiation to a stronger version that adds enzalutamide. The goal is to see if the enhanced treatment keeps the cancer from progressing longer. …

This study was designed to test two experimental drugs, AAA602 and AAA802, which deliver radiation directly to prostate cancer cells. Men with high-risk localized prostate cancer would have received these drugs before surgery to remove the prostate and nearby lymph nodes. The goa…

This study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink …

This study tests whether adding a new drug (LY2157299) to the standard treatment enzalutamide can help men with advanced prostate cancer that has stopped responding to other treatments. About 60 participants will be randomly assigned to receive either the combination or enzalutam…

This study tests whether a daily high-dose omega-3 supplement (fish oil) can slow the rise of PSA levels in men whose prostate cancer has returned after initial treatment. About 40 men with a rising PSA but no spread will take either the supplement or a placebo for one year. The …

This study compares a newer hormone therapy (darolutamide) plus radiation against standard hormone therapy plus radiation for men with intermediate-risk prostate cancer. The goal is to see if the new approach controls the cancer just as well while helping men keep better erectile…

This study tested whether taking the drug abiraterone on an on-and-off schedule could help it work longer for men with advanced prostate cancer that no longer responds to hormone therapy. Nineteen men whose cancer had already responded to standard daily abiraterone were enrolled.…

This phase 2 trial tests a sequential treatment approach for men with high-risk metastatic prostate cancer that is still sensitive to hormone therapy. In the first step, patients receive hormone therapy (LHRH analog plus a newer hormonal drug like abiraterone or enzalutamide). In…

This early-phase trial tests an adaptive approach to hormone therapy for men with stage IV prostate cancer that still responds to hormone treatment. Instead of a fixed schedule, the treatment is adjusted based on PSA levels. The study includes 17 participants and combines standar…

This pilot study is testing whether robot-assisted prostate removal for localized prostate cancer can be safely performed as outpatient surgery, meaning patients go home the same day. Twenty men will be enrolled and followed for one month to see if they can avoid a conventional h…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This study looks at how well a new robotic surgery system (Medtronic Hugo) works for urologic procedures like removing prostate, bladder, or kidney tumors. About 144 adults will have surgery with the robot, and doctors will check if the surgery is completed without switching to a…

This phase 2 trial tests whether taking omega-3 (EPA) supplements can reduce inflammation and slow cancer cell growth in men with high-risk prostate cancer who choose surgery. 130 participants will take either EPA capsules or a placebo for 14 months, starting before surgery. Rese…

This study compares two types of radiation therapy for low- or intermediate-risk prostate cancer in Asian men. One method, SBRT, delivers high-dose radiation in fewer sessions, while the other, IMRT, uses more standard daily doses. The main goal is to see which approach better pr…

This study tracks the safety of the drug TALZENNA in one man with a specific type of advanced prostate cancer that has a BRCA gene mutation and no longer responds to hormone therapy. The participant takes TALZENNA as prescribed and is monitored for side effects for up to a year. …

This phase 2 trial is testing whether a shorter course of hormone therapy (6 months instead of the usual longer duration) combined with targeted radiation can safely prevent high-risk prostate cancer from spreading. About 50 men with aggressive prostate cancer will receive hormon…

This study tested whether a shorter, more intense radiation schedule (5 sessions) works as well as the standard longer schedule (26 sessions) for men with prostate cancer. The goal was to see if the shorter treatment could control the cancer just as well, based on PSA levels afte…

This study aimed to compare two treatment plans for men with low-volume metastatic prostate cancer that still responds to hormone therapy. One group would receive hormone therapy plus abiraterone, while the other would get those two drugs plus chemotherapy (docetaxel). The goal w…

This phase 2 study is testing a combination of two drugs, SKB264 and pembrolizumab (Keytruda), in 240 people with certain advanced solid tumors, including cervical, urothelial, ovarian, prostate, and endometrial cancers. The goal is to see if the combination is safe and effective…

This early-phase study tests a new, ultra-short course of radiation therapy for men with intermediate-risk prostate cancer. The treatment uses MRI guidance to precisely target the prostate and the main tumor inside it. The goal is to see if this approach is safe and practical, wi…

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…

This phase 2 trial tests an oral drug called darolutamide (ODM-201) against standard hormone therapy (ADT) in men with prostate cancer that has not yet been treated with hormones. The main goal is to see if darolutamide can lower PSA levels as effectively as standard treatment af…

This phase 3 trial compares enzalutamide alone versus enzalutamide plus radium-223 in 446 men with castration-resistant prostate cancer that has spread to bone. The goal is to see if the combination delays cancer progression better than enzalutamide alone. Participants must have …

This study follows 80 prostate cancer patients who previously received a BioProtect balloon implant during radiation therapy. Researchers are checking for long-term side effects in the bladder and bowel, and how patients' quality of life holds up over time. The goal is to make su…

This study tests a radioactive drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. The trial aims to find the safest effective dose and see if it can lo…

This study follows 100 men with localized prostate cancer who received a condensed form of radiation called SBRT, which delivers high-dose radiation in just 5 treatments instead of the usual 42-45. Researchers are tracking how well the treatment controls cancer over time and how …

This phase 1 trial tests a combination of two radiation techniques for men with intermediate risk prostate cancer. First, a high dose of radiation is placed inside the prostate for 10-20 minutes (brachytherapy), followed by three weeks of highly targeted external radiation (SBRT)…

This phase 3 trial compares a new, shorter course of radiation (ultra-hypofractionated) to the standard longer course for men with prostate cancer that has spread to lymph nodes. Both groups also receive a brachytherapy boost and hormone therapy. The study aims to see if the shor…

This phase 3 trial is testing whether a shorter course of proton radiation (5 sessions over 1-2 weeks) works as well as the standard longer course (44 sessions over 8-9 weeks) for men with low-risk prostate cancer. The study involves 150 participants and will compare how well eac…

This early-phase trial tests whether a long-acting nerve block, given during a standard prostate biopsy, can slow the growth of high-risk prostate cancer. The block uses lidocaine and dehydrated alcohol to temporarily stop signals from nerves that may help cancer spread. Only 12 …

This study looks at whether a special PET scan called Axumin can find prostate cancer that has returned after treatment, even when another common scan (PSMA PET) shows nothing. About 50 adults with rising PSA levels and a negative PSMA PET will get an Axumin scan. The goal is to …

This study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measur…

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …

This study tests an artificial intelligence system that combines blood tests, lab data, and ultrasound images to better diagnose prostate cancer in men with borderline PSA levels (4-10 ng/mL). The goal is to reduce unnecessary biopsies by accurately identifying who truly has canc…

This study tests whether combining a special MRI analysis (called Habitat Risk Score) with blood and urine tests can more accurately rule out aggressive prostate cancer than the standard MRI reading. About 289 men with elevated PSA or abnormal exams will be enrolled. The goal is …

This study aimed to see if adding a two-minute distortion correction to standard prostate MRI scans could improve image quality and help doctors find tumors more accurately. It was designed for men who already had an MRI and biopsy. However, the study was withdrawn before any par…

This phase 3 study tests a new type of PET scan (64Cu-SAR-bisPSMA) to see if it can better detect prostate cancer that has come back after initial treatment. The study involves 220 adults with a rising PSA level after surgery or radiation. The goal is to improve detection so doct…

This early-phase trial tests TRDC002, a radioactive tracer that attaches to PSMA proteins on prostate cancer cells, to improve PET/CT imaging in patients whose cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive a sing…

This study tests whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can better detect aggressive prostate cancer in men with elevated PSA levels. About 150 men with PSA between 2-10 ng/mL and no prior biopsy will receive the scan before their standard biop…

This study looks at the best timing for a special PET scan (rhPSMA-7.3) to detect prostate cancer that has come back after prostate removal surgery. Men with a rising PSA level will get one or two scans to see when the cancer is most visible. The goal is to find the cancer early …

This study compares two types of urine samples—expressed prostatic secretion (EPS) and post-massage urine (PMU)—to see which one better predicts whether a prostate biopsy will find cancer. About 243 men scheduled for a prostate biopsy will provide both samples, and researchers wi…

This early study tests a new imaging agent called 89Zr-DFO-YS5, which attaches to a protein (CD46) found on aggressive prostate cancer cells. Thirty men with advanced prostate cancer will receive the agent and then undergo PET scans to see if the cancer lights up. The goal is to …

This pilot study is testing the world's first total-body PET/CT scanner (EXPLORER) to see if it can improve cancer imaging. Researchers will scan 9 people with prostate cancer, breast cancer, or neuroendocrine tumors using FDA-approved radiotracers. The goal is to measure how wel…

This pilot study is testing a new screening pathway for prostate cancer in men aged 55-65. Instead of relying only on PSA blood tests, participants with elevated PSA will also get a risk assessment and an MRI. The goal is to better distinguish between slow-growing cancers that do…

This study tests whether adding a PSMA PET scan helps doctors better diagnose significant prostate cancer in men whose MRI results are unclear or negative. About 660 men with no prior prostate cancer or biopsy will be randomly assigned to receive either standard care or an additi…

This early-phase trial is testing a new radioactive tracer called 18F-FTT in 30 men with prostate cancer. The tracer is designed to light up PARP-1 activity on PET/CT scans, which may help doctors see where cancer has spread. Researchers will compare the scan results with tissue …

This study compares two methods for detecting serious prostate cancer: MRI fusion biopsy and micro-ultrasound (ExactVu). Researchers want to see if micro-ultrasound can find dangerous cancers as well as MRI, and if it can be used in communities with limited healthcare access. The…

This study tests whether analyzing ultrasound images with computer software (radiomics) can better predict prostate cancer during a targeted biopsy. About 464 men aged 55 and older with suspicious prostate findings will participate. The goal is to see if this method finds more ca…

This study tests a special PET scan (18F-DCFPyL) to see if it can find prostate cancer spread that standard scans miss. Fifty men with castration-resistant prostate cancer starting enzalutamide will get the new scan. The goal is to better detect and monitor metastases, which coul…

This study looks at whether men with certain gene mutations (DRG) could benefit from a more tailored screening for prostate cancer. Researchers will test a combination of a blood test (PHI) and a special MRI scan in 320 men with or at risk for prostate cancer. The goal is to see …

This study tests a new software that combines MRI images with real-time ultrasound to guide prostate biopsies. The goal is to help doctors more accurately detect and locate aggressive prostate cancer early. About 100 men scheduled for a standard prostate biopsy will take part. Th…

This study is testing a new blood test that looks at RNA from tiny particles called exosomes to diagnose prostate cancer. Researchers will enroll 1,600 men with elevated PSA levels or other signs of prostate cancer. The goal is to see if this test can accurately detect cancer and…

This study compares tears and blood samples from men with and without prostate cancer to find clues that separate aggressive from non-aggressive disease. Researchers aim to develop a simple diagnostic tool. 75 men aged 35-85 who are being checked for prostate cancer will provide …

This study aimed to test an abbreviated MRI method (using restriction spectrum imaging plus T2-weighted images) for detecting prostate cancer, comparing it to the standard multiparametric MRI. The goal was to see if the faster, cheaper scan could find cancer just as well, while a…

This study is testing whether a special PET scan using PYLARIFY can find prostate cancer that has spread beyond the prostate in men with favorable intermediate risk cancer. About 274 men will receive one injection and scan, then be followed for up to a year. The goal is to see if…

Men with BRCA1 or BRCA2 gene mutations have a higher risk of early and aggressive prostate cancer. This study tests whether using a special MRI (multispectral 3T MRI) can find prostate cancer earlier than standard PSA and digital rectal exams. Sixty men aged 50 and older with BRC…

This study follows 7,500 men aged 50-74 to see which prostate cancer screening method works best over time. Some men were invited for a standard PSA test, while others had a newer approach using PSA plus a biomarker test and MRI. Researchers will track prostate cancer deaths, dia…

This study is testing whether a type of PET scan called PSMA PET is more accurate than standard scans (like CT or bone scans) for monitoring prostate cancer. About 58 men with progressive prostate cancer will receive an injection of a radioactive tracer and then undergo PET/CT im…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

This study explores whether aerobic exercise, like walking, can lower levels of ctDNA (a marker of cancer in the blood) and help prevent breast, prostate, or colorectal cancer from coming back. Researchers will test different amounts of weekly exercise (90 to 375 minutes) in 33 p…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This trial tests a biodegradable gel called SpaceOAR Vue that is injected between the prostate and rectum before radiation therapy. The gel temporarily pushes the rectum away to reduce radiation damage. About 500 men with intermediate-risk prostate cancer will be randomly assigne…

This study tests whether a structured home-based exercise program combining strength and aerobic training can improve quality of life, fitness, and immune function in 150 men with prostate cancer. Participants are randomly assigned to either the exercise program or usual care. Th…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This study looks at whether men with prostate cancer can have robotic surgery to remove the prostate and go home the same day, instead of staying in the hospital overnight. Researchers will check how many patients agree to try this approach and how well it works. The goal is to s…

This study tests whether placing a cryopreserved umbilical cord allograft around nerves during robotic prostatectomy helps men regain erectile function and bladder control sooner. About 100 men with prostate cancer will be randomly assigned to receive either standard surgery or s…

This study compares group telemedicine appointments to individual video visits for men with prostate cancer who are on active surveillance. Researchers want to see if the group format is practical and acceptable, and how it affects patient satisfaction and quality of life. The st…

This study compares two types of radiation therapy for low- or intermediate-risk prostate cancer: proton therapy (PBT) and intensity-modulated radiation therapy (IMRT). Both are thought to be equally effective at treating the cancer, but it's unclear which causes fewer side effec…

This study looks at whether giving a numbing injection (called a TAP block) early or late during robotic prostate surgery helps reduce pain afterward. About 94 men with prostate cancer will take part. The goal is to find the best timing to lower pain scores and the need for stron…

This study tests a 3-month strength training program designed for Hispanic prostate cancer survivors and their caregivers. Participants exercise together in remote group classes to improve physical and mental health. The goal is to see if the program is practical and helpful for …

This study looks at whether giving men a deeper level of muscle relaxation during robotic prostate surgery can lower the pressure used during the operation and reduce pain afterward. About 139 men having this surgery will be randomly assigned to either deep or moderate muscle rel…

This study tests whether giving magnesium sulfate during prostate surgery can lower pain and reduce the need for strong painkillers. About 68 adults having robotic prostate surgery will either receive magnesium or not, as part of their standard anesthesia. Researchers will compar…

This study tests whether a special cooling mat can reduce hot flashes and night sweats in people taking hormone therapy for breast or prostate cancer. About 40 participants will use the mat for 8 weeks and track their symptoms. The goal is to see if this simple, non-drug approach…

This study looks at whether combining exercise, supportive counseling, and a stimulant drug (methylphenidate) can help reduce severe fatigue in prostate cancer patients who are receiving radiation and hormone therapy. About 175 adults with prostate cancer and daily fatigue will b…

This study planned to compare two types of pelvic floor rehabilitation for men who still have urinary incontinence more than a year after prostate removal. One method uses standard Kegel exercises, while the other focuses on whole-body postural control. The goal was to see which …

This pilot study tests whether a pelvic floor muscle exercise program, taught by a physical therapist before and after radical prostatectomy, is feasible and acceptable for men with prostate cancer. The researchers will track how many patients join, stick with the program, and co…

This study tests a new way to give radiotherapy for men with intermediate-risk prostate cancer. The goal is to lower the dose to healthy parts of the prostate while boosting the dose to the tumor, using a special MRI-guided machine (MR-linac). Twenty men will take part to see if …

This study tests whether placing a Urolift device in the prostate before stereotactic body radiation therapy (SBRT) can reduce urinary side effects like frequent urination, pain, and nighttime trips to the bathroom. About 20 men with both prostate cancer and benign prostatic hype…

This study looks at whether a 16-week home exercise program can help Black and Hispanic patients with breast, colorectal, or prostate cancer become more active during chemotherapy. Participants will do aerobic and resistance exercises either with virtual supervision or on their o…

This study tests a 4-month community program called Men Moving Forward for African-American men who have finished prostate cancer treatment. The program includes twice-weekly sessions to help participants eat more fruits and vegetables, cut down on red meat, and increase physical…

This study tests whether a gentle electrical current applied to specific points on the skin (AcuTENS) can reduce pain and anxiety during a prostate biopsy. About 53 men having their first biopsy will receive either active AcuTENS or a placebo device, on top of standard numbing me…

This study looks at whether adding tramadol or magnesium to a standard local anesthetic (ropivacaine) for a nerve block can better control pain during and after robotic prostate removal. Ninety men aged 40-80 will be randomly assigned to receive one of three solutions: ropivacain…

This study tests whether a live, personalized exercise and meditation coaching program, delivered through a digital app, can improve the quality of life for cancer survivors. The trial involves 146 adults who have had breast, lung, prostate, colorectal, or other cancers. Particip…

This pilot study tests whether acupuncture can reduce frequent nighttime urination (nocturia) in prostate cancer survivors. Researchers will give 60 participants up to 10 acupuncture sessions over 10 weeks and track changes in nocturia, sleep, hot flashes, and mood. The goal is t…

This trial tests a new surgical method called NeuroSAFE, which uses real-time tissue analysis during robotic prostate removal to help surgeons avoid damaging nerves that control erections and bladder function. About 407 men with prostate cancer will be randomly assigned to receiv…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find tumors that are hard to see on CT scans. About 3,900 adults with certain cancers or growths will have their biopsy or ablation procedure done using this smart needle. The g…

This study looks at whether combining a genetic test called the Genomic Prostate Score (GPS) with MRI scans can help doctors better choose men with prostate cancer for focal therapy, which treats only the cancerous part of the prostate. Researchers will analyze data and tissue sa…

This study is not testing a new treatment. Instead, it observes how 400 men with advanced prostate cancer are actually treated in Russia, and looks for biomarkers in their tumor samples. The goal is to understand current practices and identify factors that might influence outcome…

This study looks at prostate cancer tissue from men undergoing prostate removal surgery to find cells that may be especially aggressive and resistant to treatment. Researchers give a special dye (pimonidazole) before surgery to mark oxygen-starved areas, then analyze the removed …

This study tests a new type of MRI that uses a special substance (hyperpolarized pyruvate) to see how active prostate cancer tumors are. Researchers want to know if this scan can find aggressive cancers and show if treatments are working or stopping sooner than standard scans. Ab…

This study looks back at the records of 625 men who had robotic prostate surgery for localized prostate cancer. It compares a newer single-port method with the standard multi-port approach to see which leads to fewer complications and better urinary control. The goal is to gather…

This study is testing whether artificial intelligence can predict if prostate cancer has spread to lymph nodes or other parts of the body by analyzing biopsy tissue images. Researchers will use samples from 3,000 men to develop and validate the AI model. The goal is to help docto…

This study is developing an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing a more severe form called castration-resistant prostate cancer. The AI will analyze MRI images, biopsy slides, and clinical data from…

This study tests new ways to help rural primary care clinics provide better follow-up care for cancer survivors. Researchers will give clinics telementoring, quality improvement coaching, and an obesity management toolkit. The goal is to see if these tools help clinics follow nat…

This study tests whether an AI tool can help doctors quickly and fairly identify prostate cancer patients who might qualify for a clinical trial. Researchers will use AI to rank patient records by how well they match trial criteria, then check the results. The goal is to see if t…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study follows 214 men treated for prostate cancer to see how many develop lower limb lymphedema (leg swelling) and who is most at risk. Participants attend check-ups every three months for 18 months. The goal is to better understand this side effect and its impact on quality…

This study examines 15 proteins on prostate cancer cells from 1,600 patients to see which ones are common and whether they relate to survival. Researchers will analyze stored tissue samples and collect new ones from men with advanced cancer. The goal is to understand these protei…

This study looks at how genetic differences (SNPs) in prostate cancer patients affect their response and side effects to the drug abiraterone. Researchers will analyze DNA from 600 patients taking abiraterone plus prednisone and bicalutamide. The goal is to find genetic markers t…

This study tests whether a program that educates and supports doctors can help them follow national guidelines for prostate cancer imaging. About 58 VA doctors and staff took part. The goal is to reduce inappropriate scans for low-risk patients and ensure appropriate scans for hi…

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This pilot study looks at whether special scans (PSMA PET/MRI) and genetic tests can predict how well high-risk prostate cancer responds to hormone therapy and radiation. Thirty participants will be followed for up to 5 years. The goal is to find markers that identify poor respon…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This study tests whether artificial intelligence can help doctors outline the prostate on ultrasound images for a type of radiation treatment called brachytherapy. Thirty-six adults with prostate cancer will have their treatment plans made both with and without AI assistance. The…

This study looks at how a new, more sensitive type of PET scan (PSMA PET) affects the anxiety, decision-making, and quality of life of 350 men with prostate cancer. Participants will fill out surveys about their feelings and experiences over a year. The goal is to understand the …

This study involves 400 men with high-risk prostate cancer who have not yet received treatment. Researchers are using a special type of scan called PSMA PET to see if it can find cancer that has spread to lymph nodes or other parts of the body, which standard scans often miss. Th…

This study tests a small implantable device that is placed inside prostate tumors to see how they respond to different cancer drugs. About 35 men scheduled for prostate removal surgery will receive the device before their operation. The goal is to learn whether this approach is s…

This study aimed to see if a specially designed website could help men with low-risk prostate cancer understand their treatment options and feel more confident in their choices. The researchers planned to enroll patients and measure their knowledge and decision-making satisfactio…

This observational registry will follow 500 men with metastatic castration-resistant prostate cancer who are receiving PSMA theranostics (177Lu-PSMA) as part of their standard care. Researchers will track how well the treatment lowers PSA levels and monitor any serious side effec…

This study compares infection rates in 300 men undergoing transperineal prostate biopsy, half receiving antibiotics and half not. The goal is to see if omitting antibiotics is safe. If proven, it could reduce unnecessary antibiotic use and side effects.

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study looks at how robotic surgery for prostate, bladder, or kidney cancer affects patients' finances. Researchers will ask 120 people who had surgery in the last year to fill out questionnaires about their medical costs, travel expenses, and support needs. The goal is to un…

This pilot study tests a new MRI technique that uses a special form of bicarbonate to measure how acidic prostate tumors are. Ten men with localized prostate cancer will receive an injection of hyperpolarized bicarbonate before an MRI scan. The goal is to see if this method is sa…

This study looks at how Spanish-speaking Latiné men cope after prostate cancer treatment, especially with issues like erectile dysfunction and urinary problems. Researchers will survey and interview 55 survivors to understand their needs and cultural barriers. The goal is to crea…

This study looks at whether hormone therapy (like Lupron or Casodex) changes thinking abilities in men aged 65 and older with prostate cancer. Researchers will compare cognitive function over time between men starting hormone therapy, those who have never had it, and those who ha…

This study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…

This study tests whether a special PET scan, done before prostate removal surgery, can predict if prostate cancer will come back. About 175 men with high-risk prostate cancer will get the scan, then have surgery, and be followed for up to 5 years. The goal is to see if this scan …

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This study looks back at 40 men with early-stage prostate cancer to compare two standard treatments: open surgery to remove the prostate and radiation therapy. The goal is to see which approach better controls the tumor and prevents recurrence. The results may help guide future t…

This study follows 304 men in Martinique diagnosed with prostate cancer from 2020 onward. Researchers use digital questionnaires to track changes in quality of life, especially sexual and urinary issues. The goal is to gather data to improve care and reduce health gaps in the Car…

This study follows 200 men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy) for at least 6 months. Researchers want to understand how this treatment affects the heart over time, and how factors like medical history, race, income, and access to…

This study looks at whether detailed analysis of MRI scans (called radiomics) can better predict how aggressive a prostate cancer is and whether it will come back soon after surgery. Researchers will study 125 men with prostate cancer who have an MRI before treatment. The goal is…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study follows 490 men with low-risk prostate cancer in Brazil to see how well active surveillance works. Active surveillance means closely monitoring the cancer instead of treating it right away. The goal is to learn how often the cancer changes and how many men avoid treatm…

This study looks at how often prostate cancer survivors experience faecal incontinence (loss of bowel control) after a specific type of radiation therapy. Researchers will track 200 survivors and measure the radiation dose received by the anal sphincter to see if higher doses lea…

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…

This study collects tissue, blood, and other fluid samples from men with prostate conditions, including those with no cancer, localized disease, or advanced stages. Researchers will analyze genetic changes and protein markers to understand why some men get prostate cancer, why so…

This pilot study tests whether a smartphone app called Prostate Cancer Genius can help African American men learn about prostate cancer and complete a home-based PSA test. Eighty men aged 55 to 69 from Oklahoma who haven't had a PSA test in two years will use either the new app o…

This study follows 250 men with prostate cancer who are receiving radiotherapy. Researchers want to see if a person's 'sense of coherence' — their ability to cope with stress — is linked to their quality of life and how they rate their own health. Participants fill out questionna…

This study looks at whether the Decipher test, which predicts how aggressive prostate cancer is, works the same for African-American men as for other men. The test was developed mainly from samples of European men, but African-American men have higher rates of prostate cancer and…

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to build a biobank for research into how the cancer responds to radiation. No participants were enrolled, and the study was withdrawn before it began.

This study was designed to see how much information people with breast or prostate cancer can recall about their screening and diagnosis. Researchers planned to give participants access to their online medical records and then test if that helped them remember more accurately. Ho…

This study was designed to test whether using smaller or larger stitches during robotic prostate surgery helps men regain bladder control faster. It planned to enroll men with prostate cancer undergoing robotic prostate removal. However, the trial was withdrawn before any partici…

This study looks at whether standard hormone therapy (apalutamide, darolutamide, or enzalutamide) can increase the visibility of prostate cancer cells on PSMA PET/CT scans. About 9 men with recurrent prostate cancer will take the hormone pill for a few weeks and then get a scan. …

This study looks at new ways to predict how prostate cancer and nearby healthy tissues react to a precise type of radiation therapy called SBRT. Researchers will analyze breath samples, blood DNA, and CT scans from 60 men with low- or intermediate-risk prostate cancer. The goal i…

This study looks at whether non-invasive tests—like blood, urine, and genetic analysis—can help track prostate cancer progression without repeated biopsies. Researchers will follow 500 men with low, intermediate, or high-risk prostate cancer as they receive standard care. The goa…

This study tests a method called KIM that tracks the prostate's position during radiation using implanted gold markers. If the prostate moves more than 3mm, the radiation beam stops and is repositioned. The goal is to see if this technique is feasible in 100 men receiving radiati…

This study looks for genetic changes that raise the risk of prostate cancer, especially in men diagnosed young or with a family history. Over 23,800 men with prostate cancer provided DNA samples. The goal is to find inherited genes linked to the disease, which could improve risk …

This study looks at how safe and doable different amounts of aerobic exercise are for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. About 60 participants will exercise at home while using apps and devices to track their activity. The …

This study looks at how prostate cancer changes after radiation treatment using special MRI scans. Researchers want to see if these scans can help doctors manage treatment better and sooner. About 120 men with prostate cancer who are getting radiation will take part.

This study looks at how screening for social needs (like food, housing, and transportation) and connecting Black breast and prostate cancer survivors with community health workers can improve their quality of life and well-being. Researchers are also testing anti-racism training …

This study looks at whether removing lymph nodes during prostate cancer surgery helps prevent the cancer from coming back in men with intermediate-risk prostate cancer. Currently, the procedure is standard but can cause side effects like swelling, blood clots, or nerve injury. Th…

This study looks at whether a protein in the blood called chromogranin A (CgA) can help predict if prostate cancer will come back after radiation therapy. Researchers will measure CgA levels in 118 men before, during, and after treatment. The goal is to see if changes in CgA are …

This study reviews the results of robotic prostate surgery in over 1,500 men with prostate cancer. Researchers are collecting data on patient characteristics and surgical outcomes, including survival and cancer recurrence. The goal is to understand how well the surgery works and …

This study is looking at how things like diet, physical activity, and other lifestyle habits might affect a man's risk of getting prostate cancer. Researchers are studying more than 2000 men who are at higher risk to find biological markers in the blood that could help predict ri…

This study follows nearly 2,000 men with newly diagnosed prostate cancer to see if certain genes increase the risk of the cancer spreading. Researchers will analyze genetic markers to better predict who might face more aggressive disease. The goal is to improve early detection of…

This study explores whether advanced MRI scans can detect early changes in prostate tumors and nearby healthy tissues during radiation therapy. By spotting these changes sooner, doctors might adjust treatment to improve effectiveness and reduce side effects. The study involves 38…

This study analyzes medical records and biopsy samples from 3,350 men diagnosed with localized prostate cancer between 1990 and 2006. The goal is to identify biological, pathological, and clinical markers that can predict how the disease will progress. By understanding these fact…

This study was designed to explore how the drug ruxolitinib affects immune cells inside prostate tumors. Researchers planned to give the drug to men with prostate cancer for 28 days before their scheduled surgery, then analyze tumor and blood samples. However, the study was withd…

This study collects tissue and blood samples from 156 people with advanced prostate, kidney, or bladder cancers. Researchers analyze these samples to find genetic markers that predict how well different treatments will work. Participants do not receive any experimental treatment …

This study looks at whether a special type of MRI, called RSI-MRI, can predict how well prostate cancer responds to radiation and hormone therapy. About 100 men with high-risk, localized prostate cancer will get this MRI before and during treatment. The goal is to see if the scan…

This study aimed to test a focused radiation treatment (HDR brachytherapy) for men whose prostate cancer returned only in the prostate gland after earlier radiation therapy. It planned to enroll adults with biopsy-confirmed recurrence seen on a special PET scan. However, the stud…

This study looks at how prostate cancer survivors' thinking and memory (called cognitive function) may be linked to other health issues like anxiety, depression, and trouble sleeping. Researchers will also examine how social factors, cancer details, and treatments might play a ro…

This study looks at a simpler way to offer genetic testing to people with ovarian, prostate, or pancreas cancer. Instead of always sending patients to a genetic counselor, doctors and surgeons would offer the test directly, and counselors would share results by phone. Researchers…

This study looks at whether a 2-minute animated video can help men with early-stage prostate cancer better understand their treatment options. About 400 men will watch the video and then choose between active surveillance, focal therapy, or standard treatments. Researchers will t…

This study was designed to see if a person's race or ethnicity changes how well a combination of drugs (niraparib, abiraterone acetate, and prednisone) works for a specific type of advanced prostate cancer. It planned to compare Black or Hispanic participants with White or Native…

This study looks at whether a simple genetic test can identify men who are more likely to have prostate cancer, so screening can be focused on them. About 300 Caucasian men aged 55 to 69 will provide a DNA sample and, if their genetic risk score is high, they will be offered a pr…

The IMPACT study is an international effort to screen men aged 40-69 who carry BRCA1, BRCA2, or mismatch repair gene mutations, which raise their risk of prostate cancer. Participants receive annual PSA tests and optional biopsies if levels are high. The goal is to learn how ofte…

The IMPACT Study is testing two online tools—GeneSHARE and LivingLabReport—to help people with inherited cancer gene variants share their results with family members and follow cancer screening guidelines. The study involves 720 adults who have a genetic variant linked to cancers…

This study was designed to observe changes in certain immune system proteins (chemokines) in the blood and urine of men with prostate cancer over time. Researchers planned to collect samples from patients starting new treatments, but the study was withdrawn before any participant…

This pilot study tests a new assessment tool called IA3-CP for cancer patients aged 65 and older. The tool gathers information on aging-related issues, mental health, health behaviors, and social factors to help doctors provide better, more personalized care. 35 participants are …